Vinge Logotype
Svenska English 18D7E0DE-2035-40AE-A740-8F45A358A8F4 Login
  1. Home
  2. Mandates
  3. Vinge advises Xspray Pharma in connection with a directed share issue (1)
Mandate

Vinge advises Xspray Pharma in connection with a directed share issue

December 10, 2018 Capital Markets and Public M&A

The board of directors of Xspray Pharma AB (publ) has resolved on a directed new issue of shares, whereby Xspray Pharma will raise proceeds of approximately SEK 92 million, before issue costs. 

Xspray Pharma is a product development company with several product candidates in clinical development. Xspray Pharma uses its patented RightSize technology to develop improved generic versions of marketed drugs, primarily protein kinase inhibitors (PKIs) for the treatment of cancer. 

Vinge’s team has consisted of Dain Hård Nevonen, Nils Fredrik Dehlin, Edin Agic and Julia Hirschberg.

Related

Vinge advises Axcel in connection with the launch of Accru Partners, a new group within accounting, tax, audit and advisory services

 Vinge has advised the Nordic private equity firm Axcel in connection with its establishment of Accru Partners, a new group of 22 independent firms in Sweden within accounting, tax, audit and other advisory services.
October 04, 2024

Vinge advises Irisity in connection with issue of units

 Vinge advises Irisity AB (publ) in connection with its rights issue of units consisting of shares and warrants. The issue is guaranteed to 80 per cent through subscription commitments and external guarantors.
October 03, 2024

Vinge has advised the municipality of Varberg in legal proceedings regarding a detailed development plan for a new residential area

 The detailed development plan for approximately 50 new homes in Trönningenäs, north of the city of Varberg, was adopted by the municipality on 23 February 2023. It was subsequently appealed in several stages. By decision of the Land and Environment Court of Appeal, the plan become legally binding on 2 October 2024.
October 03, 2024